Foundation Asset Management’s Theravance Biopharma TBPH Stock Holding History

Foundation Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$616K	Sell	27,154 -372,383	-93%	-$8.84M	0.53%	19
2018 Q1	$9.69M	Sell	399,537 -32,995	-8%	-$906K	3.59%	13
2017 Q4	$12.1M	Hold	432,532	–	–	3.63%	15
2017 Q3	$14.8M	Sell	432,532 -18,774	-4%	-$614K	4.62%	7
2017 Q2	$18M	Hold	451,306	–	–	5.99%	6
2017 Q1	$16.6M	Sell	451,306 -57,777	-11%	-$1.85M	5.77%	10
2016 Q4	$16.2M	Buy	509,083 +85,202	+20%	+$2.64M	4.93%	8
2016 Q3	$15.4M	Sell	423,881 -85,000	-17%	-$2.37M	5.2%	9
2016 Q2	$11.5M	Hold	508,881	–	–	3.84%	11
2016 Q1	$9.57M	Hold	508,881	–	–	2.74%	14
2015 Q4	$8.34M	Sell	508,881 -75,000	-13%	-$1.19M	2.74%	14
2015 Q3	$6.42M	Hold	583,881	–	–	1.8%	18
2015 Q2	$7.6M	Hold	583,881	–	–	2.11%	16
2015 Q1	$10.1M	Sell	583,881 -350,000	-37%	-$6.42M	2.59%	15
2014 Q4	$13.9M	Buy	933,881 +78,265	+9%	+$1.36M	3.34%	12
2014 Q3	$19.7M	Buy	855,616 +396,382	+86%	+$11.5M	5.41%	7
2014 Q2	$14.6M	Buy	+459,234	New	+$13.8M	4.2%	12

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Foundation Asset Management's TBPH Position: Q2 2018 in Review

Foundation Asset Management reduced its Theravance Biopharma (TBPH) stake by 93% in Q2 2018, selling an estimated $8.84M and leaving 27,154 shares worth $616K. The position accounts for 0.53% of the portfolio, ranked #19.

Foundation Asset Management first reported a position in TBPH in Q2 2014 and has held it in 17 quarters since. The position peaked at $19.7M in Q3 2014. 86 funds tracked by Wall St. Rank hold TBPH as of Q2 2018.

Foundation Asset Management held 27,154 shares of Theravance Biopharma worth $616K as of Q2 2018.
Foundation Asset Management sold 372,383 Theravance Biopharma shares in Q2 2018, an estimated $8.84M.
Theravance Biopharma made up 0.53% of Foundation Asset Management's portfolio in Q2 2018, its #19 holding.
Foundation Asset Management first reported a position in Theravance Biopharma in Q2 2014 and has held it in 17 quarters since.
Foundation Asset Management's Theravance Biopharma position peaked at $19.7M in Q3 2014.
86 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2018.

Based on Foundation Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.